Brind.

FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.

3 reports, 3 independent Updated Nov 1
Gone quiet
Reports
3
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Inovio's Voceryq received accelerated approval from the FDA.1 source
  2. FDA grants accelerated approval to INO-3107 following mid-cycle review.1 source
  3. Inovio received mid-cycle review from the FDA for INO-3107 and appointed EY as its accounting firm.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped